Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, abarelix (Plenaxis®) cannot be endorsed for use within NHS Wales for the initiation of hormonal castration in patients with advanced or metastatic hormone-dependent prostate cancer, if androgen suppression is appropriate. |
||
|
||
Medicine details |
||
| Medicine name | abarelix (Plenaxis®) | |
| Formulation | 100 mg powder and solvent for suspension for injection | |
| Reference number | 354 | |
| Indication | For the initiation of hormonal castration in patients with advanced or metastatic hormone-dependent prostate cancer, if androgen suppression is appropriate |
|
| Company | Speciality European Pharma Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 04/02/2011 | |